Evidences for real-life use in fragile patients: Renal failure and cancer
|
|
|
- Helen Tyler
- 6 years ago
- Views:
Transcription
1 Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA
2 Evidences for real-life use in fragile patients: Renal failure and cancer Stroke prevention in AF patients Treatment of venous thromboembolism
3 Clinical Frailty Scale
4 Major bleeding # (%) Rivaroxaban for the Treatment of Frail VTE patients *One or more of: >75 years old, CrCl <50 ml/min, low body weight ( 50 kg) 6 73% RRR 3.2% ARR Enoxaparin/VKA Rivaroxaban 5 p interaction = ,5 Recurrent VTE: Frail 4 Recurrent VTE: Non-frail ,3 1,1 0,9 n=37 n=30 n=35 n=10 Non-frail Frail 0,1 Favours 1 Favours 10 Rivaroxaban Enox/VKA Major bleeding: Frail # Major bleeding: Non-frail # Prins MH et al, Thromb J 2013;11:21
5 Use in fragile patients: Cancer Stroke prevention in AF patients Treatment of venous thromboembolism
6 NOACs in cancer-associated VTE Recurrent VTE 6 studies: 1132 patients with cancer at baseline Vedovati et al, CHEST 2015 Vedovati et al. CHEST 2015
7 DOACs for cancer-associated VTE: meta-analysis Major Bleeding Study or Subgroup AMPLIFY 2013 EINSTEIN DVT & PE 2013 HOKUSAI 2013 RECOVER I & II 2013 DOA Comparator Odds Ratio Odds Ratio Events Total Events Total Weight 18.2% 37.7% 13.4% 30.7% M-H, Fixed, 95% CI 0.45 [0.08, 2.51] 0.62 [0.21, 1.83] 1.54 [0.36, 6.61] 0.81 [0.27, 2.47] M-H, Fixed, 95% CI Total (95% CI) % 0.77 [0.41, 1.44] Total events Heterogeneity: Chi² = 1.40, df = 3 (P = 0.70); I² = 0% Test for overall effect: Z = 0.81 (P = 0.42) Favors DOA Favors comparator 3.2% vs 4.2% Vedovati Vedovati et al. Chest CHEST 2015
8 EINSTEIN DVT/PE : Pooled Cancer Subanalysis 8281 patients randomized in EINSTEIN DVT and PE ITT analysis (n=8,281 ) Safety analysis (n=8,246) No known cancer (n=7,157) History of cancer (n=469) Active cancer at baseline (n=462) Active cancer during study (n=193) Prins M et al. Lancet Haematol 2014;1:e37 e46
9 Event in patients with active cancer* (%) EINSTEIN DVT/PE Pooled Analysis: Patients with Active Cancer 655 patients with active cancer at baseline or during the study period % relative risk reduction p= ,0 Rivaroxaban Enoxaparin/VKA Efficacy # 8 6 5,0 7,0 p=0.047 (Superiority) 5,0 7,0 Major bleeding Recurrent VTE 2,0 n=16 n=20 n=8 n=15 n=25 n=38 Major bleeding Net clinical benefit # #, composite of recurrent VTE and major bleeding. Net clinical benefit #, 0,1 Favours 1 Favours 10 rivaroxaban Enox/VKA Modifed from: Prins MH et al. Lancet Haematol 2014;1:e37 e46
10 Recurrent Venous Thromboembolism Across Subgroups Rivaroxaban Standard anticoagulation n/n (%) n/n (%) All patients 36/2505 (1.4) 47/2010 (2.3) Age <60 years 17/1286 (1.3) 16/785 (2.0) 60 years 19/1219 (1.6) 31/1225 (2.5) Weight 70 kg 8/522 (1.5) 13/495 (2.6) >70 <90 kg 8/843 (0.9) 18/663 (2.7) 90 kg 11/599 (1.8) 12/482 (2.5) Active cancer at baseline Yes 5/144 (3.5) 14/338 (4.1) No 31/2361 (1.3) 33/1672 (2.0) First available CrCl <50 ml/min* 1/98 (1.0) 3/194 (1.5) 50 <80 ml/min 6/410 (1.5) 11/366 (3.0) 80 ml/min 20/1047 (1.9) 21/757 (2.8) Note: some demographic parameters have data missing; * HR not calculated because of too few events Propensity score-adjusted population HR (95% CI) 0,1 1 Favours 10 Favours rivaroxaban standard anticoagulation Ageno W et al, Lancet Haematol 2016;3(1):e12 21
11 Treatment-Emergent Major Bleeding Across Subgroups Rivaroxaban Standard anticoagulation n/n (%) n/n (%) All patients 19/2505 (0.8) 43/2010 (2.1) Age <60 years 8/1286 (0.6) 11/785 (1.4) 60 years 11/1219 (0.9) 32/1225 (2.6) Weight 70 kg 7/522 (1.3) 14/495 (2.8) >70 <90 kg 3/843 (0.4) 14/663 (2.1) 90 kg 6/599 (1.0) 12/482 (2.5) Active cancer at baseline Yes 2/144 (1.4) 13/338 (3.8) No 17/2361 (0.7) 30/1672 (1.8) First available CrCl <50 ml/min 3/98 (3.1) 9/194 (4.6) 50 <80 ml/min 3/410 (0.7) 10/366 (2.7) 80 ml/min 12/1047 (1.1) 16/757 (2.1) Note: some demographic parameters have data missing Propensity score-adjusted population Ageno W et al, Lancet Haematol 2016;3(1):e12 21 HR (95% CI) 0,01 0,1 1 Favours 10 Favours rivaroxaban standard anticoagulation
12 Real World rivaroxaban for cancer-associated VTE mean follow-up of years D.M.Bott-Kitslaar 2016 Am J of Med
13 CALLISTO: Addressing Evidence Gaps in CAT Data gaps Effectiveness and safety of rivaroxaban for the prevention and treatment of CAT Currently Ongoing QAI Treatment satisfaction, treatment persistence and quality of life in cancer patients receiving rivaroxaban Effectiveness and safety of rivaroxaban for extended treatment (>6 months) of CAT Drug drug interactions between rivaroxaban and commonly used cancer therapies Dosing in patients with chemotherapy-induced side effects How to? Manage temporary interruptions of rivaroxaban for invasive procedures Provide continuous anticoagulation for patients with chemotherapy-induced side effects PD, pharmacodynamics; PK, pharmacokinetics; QAI, Quality Improvement Initiative/Clinical Pathway; VTEp, VTE prevention; VTEx, VTE treatment
14 Caravaggio: Study design Randomized, open-label, PROBE, non inferiority study Confirmed proximal DVT Confirmed PE <72 hours R Treatment period: 6 months Apixaban Apixaban 10 mg bid 5 mg bid Dalteparin 200 IU/kg od Dalteparin 150 IU/kg od Day 1 Day 7 Day 30 6 months 30 days observation period
15 REAL-LIFE USE OF NOACs IN PATIENTS WITH CANCER ASSOCIATED VENOUS THROMBOEMBOLISM: DATA FROM A PROSPECTIVE COHORT Maria Cristina Vedovati University of Perugia
16 Use in fragile patients: Renal failure Stroke prevention in AF patients Treatment of venous thromboembolism
17 Pharmacological Characteristics of the NOACs Xabans DTI Rivaroxaban 3 Apixaban 2 Edoxaban 4 Dabigatran 1 Target Factor Xa Thrombin Prodrug No No No Yes Oral bioavailability %* 50% 62% 6.5% Renal clearance of absorbed active drug ~33% ~27% ~55 60% >80% T max (h) # Half-life (h) Fixed dosing (AF indication) od bid od bid *15 20 mg to be taken with food; # Postoperative period; 1. Dabigatran SmPC; 2. Apixaban SmPC; 3. Rivaroxaban SmPC; 4. Edoxaban SmPC
18 Major bleeding* (%) Bauersachs RM et al, Thromb J 2014;12:25 VTE Treatment in Patients with Renal Impairment normal function (n=5549); mild (n=2032); moderate (n=630); severe impairment (n=20) p interaction =0.034 # 3,0 77% RRR 3.0% ARR 3,9 Enoxaparin/VKA Rivaroxaban Recurrent VTE: Moderate Recurrent VTE: Mild Recurrent VTE: Normal CrCl (ml/min) 1,0 n=29 0,8 n=23 n=30 1,4 n=14 n=12 0,9 n=3 Normal Mild Moderate 0,01 0, Favours Favours Rivaroxaban Enox/VKA Major bleeding: Moderate* Major bleeding: Mild* Major bleeding: Normal*
19 Xalia: Recurrent Venous Thromboembolism Rivaroxaban Standard anticoagulation n/n (%) n/n (%) All patients 36/2505 (1.4) 47/2010 (2.3) Age <60 years 17/1286 (1.3) 16/785 (2.0) 60 years 19/1219 (1.6) 31/1225 (2.5) Weight 70 kg 8/522 (1.5) 13/495 (2.6) >70 <90 kg 8/843 (0.9) 18/663 (2.7) 90 kg 11/599 (1.8) 12/482 (2.5) Active cancer at baseline Yes 5/144 (3.5) 14/338 (4.1) No 31/2361 (1.3) 33/1672 (2.0) First available CrCl <50 ml/min* 1/98 (1.0) 3/194 (1.5) 50 <80 ml/min 6/410 (1.5) 11/366 (3.0) 80 ml/min 20/1047 (1.9) 21/757 (2.8) Note: some demographic parameters have data missing; * HR not calculated because of too few events Propensity score-adjusted population HR (95% CI) 0,1 1 Favours 10 Favours rivaroxaban standard anticoagulation Ageno W et al, Lancet Haematol 2016;3(1):e12 21
20 XALIA: Treatment-Emergent Major Bleeding Across Subgroups Rivaroxaban Standard anticoagulation n/n (%) n/n (%) All patients 19/2505 (0.8) 43/2010 (2.1) Age <60 years 8/1286 (0.6) 11/785 (1.4) 60 years 11/1219 (0.9) 32/1225 (2.6) Weight 70 kg 7/522 (1.3) 14/495 (2.8) >70 <90 kg 3/843 (0.4) 14/663 (2.1) 90 kg 6/599 (1.0) 12/482 (2.5) Active cancer at baseline Yes 2/144 (1.4) 13/338 (3.8) No 17/2361 (0.7) 30/1672 (1.8) First available CrCl <50 ml/min 3/98 (3.1) 9/194 (4.6) 50 <80 ml/min 3/410 (0.7) 10/366 (2.7) 80 ml/min 12/1047 (1.1) 16/757 (2.1) Note: some demographic parameters have data missing Propensity score-adjusted population Ageno W et al, Lancet Haematol 2016;3(1):e12 21 HR (95% CI) 0,01 0,1 1 Favours 10 Favours rivaroxaban standard anticoagulation
21 Moderate Renal Impairment in Phase III AF Trials ROCKET AF 1 (n=14,264) ARISTOTLE 2-4 (n=18,201) ENGAGE AF 5,6 (n=21,105) RE-LY 7,8 (n=18,113) Specific renal dose studied to support safety Proportion of patients with moderate renal impairment Number of patients studied with low dose Number of patients studied with low dose with moderate renal impairment Number of patients studied with low dose with moderate renal impairment as a proportion of all patients studied with the NOAC 21%* 15% 19% 20% 15 mg OD: mg BD: mg BD # : mg BD: # % 1.6% 19.6% # 9.9% *CrCl ml/min; CrCl >30-50 ml/min; CrCl 50 ml/min; Scr 1.5 mg/dl ; egfr,<50 ml/min # Data given for dose adjusted arm of High-Dose (60/30) group as Low-Dose (30/15) regimen not approved 1. Fox KAA et al, Eur Heart J 2011;32: ; 2. Granger GB et al, N Engl J Med 2011;365: ; 3. Hohnloser SH et al, Eur Heart J 2012;33: ; 4. FDA. Clinical Review of apixaban NDA , p Giugliano RP et al, N Engl J Med 2013;369: ; 6. Bohula EA et al, Circulation 2015;132: A17169; 7. Connolly SJ et al, N Engl J Med 2009;361: ; 8. Hijazi Z et al. Circulation 2014;129:961 70
22 Cumulative event rate (%) ROCKET AF Subanalysis moderate renal impairment: efficacy Stroke or SE in patients with CrCl ml/min (Per protocol on treatment) Rivaroxaban 15 mg Warfarin (INR 2 3) Event rate Warfarin Rivaroxaban HR 0.84 (95% CI ) Days since randomization No. at Risk Rivaroxaban 1,434 1,226 1,103 1, Warfarin 1,439 1,261 1,140 1, Per-protocol on-treatment population Fox KA et al. Eur Heart J 2011;32(19):
23 Events (%/year) ROCKET AF Subanalysis Moderate Renal Impairment: safety Relevant safety endpoints in patients with CrCl ml/min (Safety on treatment population) HR=0.55 Warfarin (n=1476) (95% CI ) Rivaroxaban 15 mg od (n=1474) p interaction =0.39 1,5 HR=0.81 (95% CI ) p interaction =0.51 HR=0.39 1,0 (95% CI ) p interaction =0.53 1,39 0,5 0,88 0,76 0,71 0,74 0,28 0,0 Critical organ bleeding ICH Fatal bleeding Fox KAA et al, Eur Heart J 2011;32:
24 Cumulative hazard for major bleeding Worsening Renal Function and MB with NOACs in AF Worsening RF NO YES Time, months Becattini et al., submitted
25 ROCKET AF stroke or SE With Worsening Renal Function 3320 (26.3%) had WRF Rivaroxaban = 1632 (20 mg, 41%; 15 mg, 10%) In Rocket AF trial no dose adjustments after baseline for changing CrCl Fordyce, Circulation July
26 ROCKET AF: CRB With Worsening Renal Function In Rocket AF trial no dose adjustments after baseline for changing CrCl Fordyce, Circulation July
27 Evidences for real-life use in fragile patients: Renal failure and cancer Fragile patients have an increased risk of thromboembolic events and bleeding complications The efficacy of NOACs and in particular of rivaroxaban is confirmed in subgroups of fragile patients without safety concerns
28 Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia
Updates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
Anticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
What s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
New Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
DOACs and CAT. 05 May 2017 NTW St Thomas Hospital
DOACs and CAT Alexander (Ander) Cohen Vascular Medicine / Haematology Guy s and St Thomas Hospitals, King s College, London 05 May 2017 NTW St Thomas Hospital Disclosures for Dr. Alexander (Ander) T. Cohen
Obesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
DIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
Edoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
The spectrum of clinical outcome of PE
Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
Dabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
ADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
Clinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
ESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
New Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
Acute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
I nuovi anticoagulanti orali nella trombosi venosa profonda. Terapia della TVP. Fulvio POMERO. Medicina Interna S. Croce e Carle Cuneo
I nuovi anticoagulanti orali nella trombosi venosa profonda Terapia della TVP Fulvio POMERO Medicina Interna S. Croce e Carle Cuneo 1 2 3 Poor VKA control (first 90 days) Good VKA control (first 90 days)
The clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation Wednesday, March 28, 2018, 1:00PM ET Presenters: John Fanikos, RPh, MBA Curt Mahan, PharmD Paul Dobesh, PharmD, FCCP, BCPS Presenters
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach. Dr. Johan Kurnianda, SpPD-KHOM
New Perspective in VTE Treatment in Acute Medically Ill Patients: Single vs. Dual Drug Approach Dr. Johan Kurnianda, SpPD-KHOM VTE : Spectrum of Disease Deep Vein Thrombosis Post Thrombotic Syndrome Pulmonary
Anticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
Modern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
Edoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
Cancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
DOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
New Strategies and New Data- Beyond Guidelines
New Strategies and New Data- Beyond Guidelines Anthony Maraveyas GESCAT Lisbon 13 th October 2018 G.MA.GM.XA.12.2017.1962 Conflict of Interest Statement 2 u Research Support: Bayer, Boehringer Ingelheim,
Drug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
Old and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
Cancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
Oral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
Incidence and Impact of Antithrombotic-related Intracerebral Hemorrhage
Incidence and Impact of Antithrombotic-related Intracerebral Hemorrhage John J. Lewin III, PharmD, MBA, BCCCP, FASHP, FCCM, FNCS Division Director, Critical Care & Surgery Pharmacy Services, The Johns
La terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
The Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
Engage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
New and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
Management of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
New oral anticoagulants and Palliative Care.
New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway
New Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
Warfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
NOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
New Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
Antithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
DOACs in SPECIAL POPULATIONS
DOACs in SPECIAL POPULATIONS Ann K Wittkowsky PharmD, CACP, FASHP, FCCP Clinical Professor University of Washington School of Pharmacy Director, Anticoagulation Services UWMedicine Department of Pharmacy
ACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
controversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
Supplementary Online Content
Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published
Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
NOACs Scegliere in Contesti Particolari
Gianluca Botto, FESC, FEHRA U.O.s. Elettrofisiologia ASST-Lariana, Como NOACs Scegliere in Contesti Particolari Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St. Jude
ADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
Do s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
Non commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
Xarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
The DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
Edoxaban. Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze
Edoxaban Domenico Prisco Dipartimento di Medicina Sperimentale e Clinica Università di Firenze SOD Patologia Medica, AOU Careggi, Firenze Bologna 8 novembre 2013 Disclosures: DP has received research support
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
PRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
Disclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
Stepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
Η ισορροπία ασφάλειας και αποτελεσματικότητας: Η συνέπεια στα αποτελέσματα των τυχαιοποιημένων κλινικών μελετών και των δεδομένων κλινικής πρακτικής της Απιξαμπάνης Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
Novel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
Anticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
Benefit risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism
Review Article 231 Benefitrisk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism Jan Beyer-Westendorf 1 ; Walter Ageno 2 1 Center for Vascular Diseases
Feedback from the EMA
Feedback from the EMA Jens Heisterberg, MD Danish Medicines Agency Is There a Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? CSRC Meeting, Washington D.C., December 3,
Managing Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
Observations from Novel Oral Anticoagulant (NOAC) Trials for Stroke Prevention in Atrial Fibrillation (SPAF)
Observations from Novel Oral Anticoagulant (NOAC) Trials for Stroke Prevention in Atrial Fibrillation (SPAF) CSRC NOAC Dosing Workshop December 3 rd, 2015 Jeffry Florian, Ph.D. Team Leader, Division of